Kyowa Kirin has agreed to acquire gene therapy developer Orchard Therapeutics for up to $477.6 million, to develop several biopharmaceutical candidates in areas including oncology and autoimmune diseases. Under the terms of the agreement, Kyowa will acquire Orchard for $16 per...

    Sanofi has agreed to buy US biotech firm Inhibrx in a deal valued at up to $2.2bn, bolstering its drug development portfolio with an experimental treatment for a rare genetic disease. Under the terms of the agreement, Sanofi will acquire all outstanding shares of...

    Bora Pharmaceuticals, a contract development and manufacturing organization (CDMO), has officially acquired Upsher-Smith Laboratories, a specialty-brand and generics company, for $210 million. Upsher-Smith, founded in 1919 and owned by Sawai since 2017, has a...

    GSK’s acquisition, which comes amid other big money moves in the pharma industry, aims to broaden its asthma drug range. GSK’s acquisition will give the company access to Aiolos’ AIO-001, a monoclonal antibody that is ready to start Phase II trials for the treatment of...